Stryker continues to enjoy extensive financial flexibility, even as it has issued more debt to finance the purchase of some larger acquisitions. At the end of 2024, the firm's net debt/EBITDA was 1.9 ...

Gross margins are projected to range from 47% to 51%, benefiting from improved transfer pricing under the Zimmer Biomet partnership. Rosa stated that the company is on track to submit a 510(k ...

Zimmer Biomet's product pipeline remains a key strength, with several innovative offerings poised to drive future growth. The ROSA Shoulder robotic application has received positive feedback ...

NeuroOne (Nasdaq:NMTC) announced today that it accelerated the anticipated timeline of the FDA submission for its nerve ablation tech.

Before I turn the call over to Mr. Rosa, I'd like to remind you that ... is a result of the deepening partnership with Zimmer Biomet. As a reminder, our relationship with Zimmer Biomet began ...

SINGAPORE, March 30, 2023 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that ROSA HIP ® with ONE Plannerâ„¢ Hip won the ...

The global orthopedic consumables market is set to witness significant growth, with market valuation expected to surge from USD 44.0 billion in 2024 to USD 60.9 billion by 2034, according to recent ...

Dave Rosa: Thanks, operator ... The strong financial performance is a result of the deepening partnership with Zimmer Biomet. As a reminder, our relationship with Zimmer Biomet began in 2020 ...

Total revenue of $6.3M Includes $3.3 Million of Product Revenue in Addition to a One-Time Upfront Payment of $3.0 Million in License Revenue from Zimmer ... Zimmer Biomet,” said Dave Rosa ...